Abstract 4533: Identification of DAT-2000A, a novel potent PARG inhibitor that selectively inhibits PARPi-resistant and homologous-recombination-deficient tumors

Abstract

Abstract A significant portion of patients with homologous recombination repair deficiencies(HRD) do not respond to PARP inhibitors, and even among those who initially respond, resistance often develops after PARP inhibitor treatment. This underscores the unmet clinical need to address the challenges in the treatment of HRD patients. Poly (ADP-ribose) glycohydrolase (PARG) plays a key role in hydrolyzing PAR chains from PARylated protein substrates, such as PARP1, serving as a critical checkpoint in DNA damage repair and the control of DNA replication stress. Therefore, PARG has emerged as a promising target for cancer therapy. Cancer cells experiencing replication stress, such as HRD breast cancer cells and those resistant to PARPi, exhibit sensitivity to PARG inhibition. DAT-2000A is a potent, selective, orally bioavailable small-molecule inhibitor of PARG, which directly binds to the catalytic domain of PARG, inducing the accumulation of poly-PAR chains at DNA lesions, and exhibits notable anti-proliferative activity across a wide range of HRD tumors both in vitro and in vivo. Biochemical assays confirm DAT-2000A's high potency and selectivity as an inhibitor of PAR-chain hydrolysis. In cellular assays, DAT-2000A demonstrates selective sensitivity in HRD cells, distinguishing itself from PARPi across various indications. Preclinical studies involving CDX and PDX xenograft models reveal that DAT-2000A exerts robust anti-tumor effects in both PARPi-sensitive and -resistant settings. Furthermore, it induces a dose and time-dependent accumulation of PAR chains, which may serve as a reliable pharmacodynamic biomarker indicative of PARG target engagement. In conclusion, DAT-2000A represents an innovative targeted therapy that warrants further investigation in clinical trials for the treatment of HRD cancers and beyond. Citation Format: Dan Yan, Yan Zhang, Zhangqi Yu, Yao Zhang, Jingxi Zhang, Bin Wang, Huixian Chen, Jingxue Shi, Zhiwei Bao, Xiaoling Lin, Jincong Zhuo, Kevin Zhou. Identification of DAT-2000A, a novel potent PARG inhibitor that selectively inhibits PARPi-resistant and homologous-recombination-deficient tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4533.